Company: TVRD
Filing Date: 2025-11-13
Form Type: 424B3
Source: 0001104659-25-111336
Chunk: 6

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-11-13
Form: 424B3
Chunk 6
---
 ​ | $      |  85,503 | ​ |   |    2,574,767 | ​ | $      |   2 | ​ | $          |     944 | ​ | $           |  -74,016 | ​ | $             |   — | ​ | $                |  -73,070 |
| Stock-based compensation                                                                             |   |               — | ​ |        |       — | ​ |   |            — | ​ |        |   — | ​ |            |      80 | ​ |             |        — | ​ |               |   — | ​ |                  |       80 |
| Net loss                                                                                             |   |               — | ​ |        |       — | ​ |   |            — | ​ |        |   — | ​ |            |       — | ​ |             |   -5,513 | ​ |               |   — | ​ |                  |   -5,513 |
| Balances as of September 30, 2024                                                                    |   |       3,963,910 | ​ | $      |  85,503 | ​ |   |    2,574,767 | ​ | $      |   2 | ​ | $          |   1,024 | ​ | $           |  -79,529 | ​ | $             |   — | ​ | $                |  -78,503 |

<div align='center'>The accompanying notes are an
integral part of these condensed consolidated financial statements.</div>

​

<div align='center'>5</div>

Table of Contents

<div align='center'>TVARDI THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited, amounts in thousands)</div>

| ​                                                                           
 ​                                                                           
 ​                                                                           
 Cash flows from operating activities:                                       | ​ 
 ​ | ​                                       
 For the Nine Months Ended September 30, 
 2025                                    
 ​                                       |       ​ | ​ | ​    
 2024 
 ​    |       ​ | ​ 
 ​ 
 ​ 
 ​ |
|:----------------------------------------------------------------------------|:--|:----------------------------------------|--------:|:--|:-----|--------:|:--|
| Net loss                                                                    | ​ | $                                       | -10,939 | ​ | $    | -16,690 | ​ |
| Adjustments to reconcile net loss to net cash used in operating activities: | ​ |